Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Payables (2016 - 2025)

Historic Payables for Regen BioPharma (RGBP) over the last 12 years, with Q4 2025 value amounting to $979038.0.

  • Regen BioPharma's Payables rose 58219.94% to $979038.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $979038.0, marking a year-over-year increase of 58219.94%. This contributed to the annual value of $1.0 million for FY2025, which is 9601.0% up from last year.
  • Regen BioPharma's Payables amounted to $979038.0 in Q4 2025, which was up 58219.94% from $1.0 million recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Payables registered a high of $1.3 million during Q1 2021, and its lowest value of $29799.0 during Q3 2022.
  • Its 5-year average for Payables is $833431.2, with a median of $1.1 million in 2023.
  • Per our database at Business Quant, Regen BioPharma's Payables crashed by 9764.93% in 2022 and then surged by 255931.42% in 2025.
  • Regen BioPharma's Payables (Quarter) stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then crashed by 92.63% to $93393.0 in 2023, then soared by 53.66% to $143512.0 in 2024, then soared by 582.2% to $979038.0 in 2025.
  • Its Payables stands at $979038.0 for Q4 2025, versus $1.0 million for Q3 2025 and $808857.0 for Q2 2025.